Lucas Maurer

Lucas Maurer

MLaw, Attorney at Law




Direct phone: +41 58 658 14 21

Curriculum Vitae

PDF download

Lucas Maurer works as an Attorney at Law at Walder Wyss. He advises clients in the fields of commercial and corporate law, mergers & acquisitions, private equity, venture capital and financings.

Born in 1990, Lucas Maurer studied at the University of Basel (BLaw 2015, MLaw 2017). After completing his traineeship at a law firm in Basel, Lucas Maurer was admitted to the bar in 2019 in the canton of Basel-Stadt. He started his professional career as Legal & Compliance Counsel in the legal department of an international medical device company (2019 - 2022). During his studies he was further able to gain professional experience in the legal and in the compliance department of an international pharmaceutical company as well as in a renowned US law firm in New York.

Lucas Maurer practices in German and English. He also speaks French and has basic knowledge in Mandarin. He is registered with the Bar Register of the Canton of Basel-Stadt and is admitted to practice throughout Switzerland.

SixPeaks Bio AG debuts with USD 110 million in Funding

Walder Wyss berät P&I Personal & Informatik AG beim Verkauf der Mirus Software AG an Alpha VCX

Axalta Coating Systems Group acquires André Koch AG

Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma

Nouscom Raises €67.5m ($72m) in Oversubscribed Series C Financing Round

CONVOTIS stärkt seine Position in der Schweiz durch die neueste Akquisition der acdalis AG, einem anerkannten Spezialisten für Managed Cloud und Infrastruktur Services.

Syz Capital und Saturnus Capital investieren in Capture Media

Zusammenschluss von SETEX und Datatex mit Elvaston

CONVOTIS startet mit der Übernahme der JMC Gruppe als Plattformunternehmen in den Schweizer IT Markt und stärkt seine Positionierung im Segment der Managed Services und digitalen Plattformlösungen.

LimmaTech Biologics Raises $37 Million Series A to Advance Its Pipeline of Vaccines Against Multidrug-Resistant Bacterial Infections

Pierre Fabre Laboratories acquires Vertical Bio AG

Das Familienunternehmen Henke-Sass, Wolf GmbH übernimmt die Zünd Präzisionsoptik AG

Alentis Therapeutics Closes USD 105m Series C Funding

BC Platforms Announces USD 20 Million Growth Financing led by Jolt Capital

Versant Ventures launches Vector BioPharma with USD 30m Series A

Engimmune Therapeutics raises CHF 15.5m in Seed Financing

Versant Ventures launches Cimeio Therapeutics with USD 50m Series A